First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Jean‐Marc Chavatte, Suma Rao, Lisa F. P. Ng, Chee Wah Tan et al.
Citations
3 citations
Journal
EBioMedicine
Topics
SARS-CoV-2 and COVID-19 Research
Field-Weighted Citation Impact (FWCI)
1.17
article
First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial
Jean‐Marc Chavatte, Suma Rao, Lisa F. P. Ng, Chee Wah Tan, Sean Wei Xiang Ong, Barnaby Edward Young, Tau Hong Lee, Yun Shan Goh, Raymond Tzer Pin Lin, Nabilah Rahman, David Chien Lye, Shirley Yun Yan Mah, Nathan Wong, Lin‐Fa Wang, Daniel R X Lim, Siew‐Wai Fong, I. Russel Lee, Yi Qing Chin, Ee Chee Ren, Laurent Rénia, Aileen Ying Yan Yeoh, Sapna P. Sadarangani, Po Ying Chia, Mihir Gandhi, Angéline Rouers, Anthony Torres‐Ruesta, Xuan Ying Poh, Ray J H Lin, Terence J K Yoong, Wanni Chia, J Jonathan Lim
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
EBioMedicineVol. 107
Institutions
Agency for Science, Technology and Research (SG), National University of Singapore (SG), Nanyang Technological University (SG), Duke-NUS Medical School (SG), National Centre for Infectious Diseases (SG), Singapore Clinical Research Institute (SG)
Funders
Agency for Science, Technology and Research, U.S. Food and Drug Administration, Medical Research Council, National Medical Research Council, Biomedical Research Council